Results 41 to 50 of about 1,314 (191)

Achieving Quiescence with Fluocinolone Implants

Case Reports in Ophthalmology, 2021
Persistent anterior uveitis causing cystoid macular oedema may necessitate either intraocular or systemic immunosuppression. This case report highlights how a newly licenced treatment, fluocinolone acetonide (Iluvien®, Alimera Sciences Ltd., England, UK)
Freia McGregor, Andrew D. Dick, Tomas Burke   +2 more
doaj   +1 more source

Retrospective Analysis of Treatment Patterns in Pseudophakic Diabetic Macular Oedema Eyes Treated with Anti‐VEGF

Journal of Ophthalmology, Volume 2021, Issue 1, 2021., 2021
Background/Objectives. Currently, in England, antivascular endothelial growth factor (anti‐VEGF) is the first‐line treatment for diabetic macular oedema (DMO) where central macular thickness (CMT) is ≥400 microns. In pseudophakic eyes with suboptimal response to first‐line therapy, intravitreal corticosteroids may also be used.
Di Zou, Imran Jawaid, Winfried M. Amoaku, Marcel Menke   +3 more
wiley   +1 more source

Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report

Case Reports in Ophthalmology, 2022
Diabetic macular edema (DME) is now a well-known condition for which a number of treatments have been shown to be effective. Intraocular corticosteroids are part of this therapeutic arsenal but are sometimes responsible for ocular hypertension.
Amina Rezkallah, Olivier Loria, Thibaud mathis, Samuel Chacun, Philippe Denis, Laurent Kodjikian   +5 more
doaj   +1 more source

Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)—results from the ILUVIT study

Graefe's Archive for Clinical and Experimental Ophthalmology, 2022
To investigate the changes in vitreous inflammatory and angiogenic cytokine levels, primarily interleukin-(IL)-6, following intravitreal injection of the 0.19 mg fluocinolone acetonide (FAc, ILUVIEN®) implant in patients with diabetic macular edema.
S. Deuchler, R. Schubert, Pankaj Singh, A. Chedid, Ninel Kenikstul, J. Scott, T. Kohnen, H. Ackermann, F. Koch   +8 more
semanticscholar   +1 more source

Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience [PDF]

, 2021
We conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME)
Agodi A., Avitabile T., Barchitta M., Bonfiglio V., Caselgrandi P., Cennamo G., Fallico M., Furino C., Longo A., Lotery A., Marolo P., Maugeri A., Reibaldi M., Russo A., Ventre L.   +14 more
core   +1 more source

Iluvien Implant for the Treatment of Cystoid Macular Edema Following Vitrectomy and Epiretinal Membrane Peel

Acta Scientific Ophthalmology, 2021
H. Zambarakji, Amany Abelaziz
semanticscholar   +2 more sources

Iluvien® in der Therapie des strahleninduzierten Makulaödems

, 2019
27. Jahrestagung der Regionalgesellschaft der Augenärzte Sachsen-Anhalts und Thüringens e. V.
Zimmermann, L, Grajewski, L, Kneifel, CE, Krause, L   +3 more
  +5 more sources

Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study

Eye, 2021
This study aimed to assess the long-term effectiveness of the 0.2 μg/day fluocinolone acetonide (FAc) implant over ≥3 years for patients with diabetic macular oedema.
C. Bailey, U. Chakravarthy, A. Lotery, G. Menon, J. Talks   +4 more
semanticscholar   +1 more source

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto, Greco A., La Cava M, Lambiase A, Limoli PG, Nebbioso M   +5 more
core   +1 more source

Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries [PDF]

, 2022
none14siIntroduction: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant delivers a continuous intravitreal corticosteroid dose for the treatment of refractory diabetic macular oedema (DMO). The aim of this study was to assess the impact of an
Arnould, Louis, Baillif, Stephanie, Barbosa-Breda, Joao, Bourredjem, Abderrahmane, Busch, Catharina, Creuzot-Garcher, Catherine, Gabrielle, Pierre-Henry, Grise-Dulac, Alice, Hamza, Mahmoud, Lebrize, Sarah, Lupidi, Marco, Mariotti, Cesare, Massin, Pascale, Rehak, Matus   +13 more
core   +2 more sources